ArticleScientific reports2026
Dysregulated expression of cell cycle regulators CDC20, PLK1, BUB1, CDC45, CDCA5 in pancreatic ductal adenocarcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with five years survival rate less than 5%. In Pakistan, transcriptomic profiling of pancreatic cancer is limited, with most evidence derived from in silico and isolated NGS analyses, highlighting the need for RNA-sequencing-based expression profiling in Pakistani PDAC cohorts. The purpose of this study is to report hub genes that are involved in progression of cancer and can be used as diagnostic and therapeutic markers. Pakistani PDAC RNA-seq dataset was pooled with seven publicly available NCBI-GEO datasets (GSE136569, GSE119794, GSE164665, GSE119224, GSE211398, GSE196009, and GSE40174) to probe common hub genes. The expression of these hub genes in tumor samples was evaluated using Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) and validated through Whole Exome Sequencing. CDC20, PLK1, BUB1, CDC45, and CDCA5 were concordantly present in seven NCI-GEO Datasets along with Pakistani RNA-seq dataset. These hub genes were upregulated at the initial stages of PDAC. RT-qPCR revealed significant upregulation in Pakistani tumor samples (*P < 0.05, **P < 0.001). WES analysis demonstrates non synonymous pathogenic variants in BUB1. The consistent dysregulated expression of the hub genes across independent NCBI-GEO datasets and the Pakistani RNA-seq cohort suggests their possible robustness across diverse populations and potential utility as broadly applicable biomarkers. These findings offer population-specific insights that may inform future biomarker-guided diagnostic and prognostic stratification of PDAC in Pakistan.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.